LB SemiconLB세미콘
061970 · KOSDAQ · ₩061970 · LB세미콘
₩3,205▼ ₩70 (2.14%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩145B | ₩134B | ₩122B | ₩126B | ₩116B | ₩117B | ₩105B | ₩119B |
| Cost of sales | ₩125B | ₩119B | ₩138B | ₩123B | ₩111B | ₩112B | ₩107B | ₩112B |
| Gross profit | ₩20B | ₩15B | −₩16B | ₩2.1B | ₩5B | ₩4.9B | −₩1.2B | ₩7.4B |
| Operating income | ₩13B | ₩7.6B | −₩26B | −₩6.3B | −₩3.3B | −₩4B | −₩10B | −₩2.2B |
| Net income | −₩1.4B | ₩10B | −₩148B | ₩8.4B | −₩8.1B | −₩2.8B | −₩16B | −₩5.7B |
| Net income to shareholders | ₩8.8B | ₩10B | −₩135B | −₩2.4B | −₩11B | −₩3.3B | −₩12B | −₩6.8B |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total assets | ₩686B | ₩694B | ₩684B | ₩769B | ₩763B | ₩835B | ₩806B | ₩771B |
| Current assets | ₩216B | ₩221B | ₩211B | ₩183B | ₩168B | ₩217B | ₩193B | ₩161B |
| Cash and equivalents | ₩41B | ₩19B | ₩33B | ₩18B | ₩12B | ₩50B | ₩72B | ₩39B |
| Total liabilities | ₩390B | ₩413B | ₩414B | ₩446B | ₩437B | ₩498B | ₩460B | ₩412B |
| Current liabilities | ₩300B | ₩321B | ₩315B | ₩328B | ₩321B | ₩341B | ₩303B | ₩260B |
| Borrowings | ₩295B | ₩319B | ₩333B | ₩359B | ₩359B | ₩396B | ₩382B | ₩329B |
| Total equity | ₩296B | ₩281B | ₩270B | ₩324B | ₩326B | ₩337B | ₩346B | ₩359B |
| Shareholders' equity | ₩285B | ₩276B | ₩266B | ₩320B | ₩322B | ₩333B | ₩230B | ₩243B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | ₩53B | −₩1B | ₩8B | ₩14B | −₩5.5B | −₩7.4B | ₩17B | ₩30B |
| Capital spending | ₩16B | ₩11B | ₩12B | ₩6.3B | ₩5B | ₩32B | ₩32B | ₩16B |
| Free cash flow | ₩37B | −₩12B | −₩4.4B | ₩8.1B | −₩10B | −₩39B | −₩15B | ₩14B |
Consolidated where available. Amounts in won.
Also known as: LB Semicon / LB세미콘 / 061970 / KRX:061970
Source: KRX statistical information